



LMA International NV

FOR IMMEDIATE RELEASE

STEADY PERFORMANCE IN DIFFICULT MARKET CONDITIONS

- Strong demand for LMA Supreme™
- Increased focus on R&D
- Improved Urology business

Singapore, 6 August 2009 – Mainboard-listed LMA International NV (“LMA” or the “Group”), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, has announced its results for second quarter (“Q2”) and first six months (“1H”) of the financial year ending December 31, 2009 (“FY2009”).

The medical device market continues to experience a difficult operating environment marked by tight liquidity, reduced capital budgets of hospitals across all markets and a drop in the global number of elective surgeries, especially in the United States. Despite this environment, Group net sales in both Q2 and 1H FY2009 were broadly flat at US\$28.5 million and US\$53.8 million, respectively, based on 2008 exchange rates. When measured at current year exchange rates net sales in 1H2009 were US\$51.6 million or 3% down on prior year.

Sales of single-use devices increased by 10% in revenue terms in 1H FY2009, driven primarily by demand for LMA Supreme™. Total number of single-use units sold grew by 13% or 0.4 million units.

In 1H FY2009, the Group reported a rise in sales of “non-anaesthesia products” to US\$1.9 million from US\$1.7 million in 1H FY2008 with improved sales of the LMA StoneBreaker™ following the exclusive distribution agreement with Cook Medical concluded in Q1 FY2009.

As part of the Group’s increased focus on research and development, expenditure increased by more than 50% in 1H FY2009 and more than doubled in Q2 FY2009.

Whilst net income (excluding the non-cash stock compensation charge) for 1H FY2009 was down by 26% to US\$5.3 million this is primarily due to the impact of changes in exchange rates year-on-year.

The Group continues to have a strong balance sheet with cash balances of US\$38.9 million and no debt as at 30 June 2009.

Post Q2 FY2009 developments

The Group has today separately announced that it plans to build its own manufacturing facility. This move will enable LMA to achieve lower cost of goods and provide additional sources of supply.

It has also recently announced its increased investment in LMA Urology to 62.5% and acquired Italia Medical Systems SRL (“IMS”). The acquisition of IMS provides LMA with an existing sales infrastructure in Italy and a platform for the Group to enhance its market share in Europe.

- ENDS -

For media queries, please contact:

Kreab Gavin Anderson, Tel: +65 6339 9110

Sharon Seetho, Email: sseetho@kreabgavinanderson.com, Mob: +65 9009 8495

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA. For more information, visit www.lmanv.com.